Brochure
9 Sep 2024
Company Brochure
PDF 2.9 MB
We care about creating quality biologics with passion!
Content provided by our supplier
Polpharma Biologics
-
PL -
2021On CPHI since
-
3Certificates
-
1000 - 4999Employees
Company types
Primary activities
Other Content from Polpharma Biologics (3)
-
News Polpharma Biologics’ investigational biosimilar shows PK/PD comparability to inflammatory bowel disease blockbuster Entyvio®
Polpharma Biologics, announced topline results demonstrating the pharmacokinetic (PK) and pharmacodynamic (PD) comparability of its biosimilar candidate PB016 to its reference drug, Entyvio®* (vedolizumab).
-
News Polpharma Biologics announces approval of Europe’s first and only biosimilar for multiple sclerosis - Tyruko® (natalizumab)
Polpharma Biologics announced that the European Commission (EC) has approved Tyruko® (natalizumab) as the first and only biosimilar for relapsing forms of multiple sclerosis (MS) in Europe. Tyruko® was developed by Polpharma Biologics and will be commercialized by its collaboration partner Sandoz.
-
News Polpharma Biologics announces FDA approval of Tyruko®
Polpharma Biologics, announced that the FDA is the first regulatory body worldwide to approve the use of Tyruko® (natalizumab-sztn) - a new biosimilar for the treatment of relapsing forms of multiple sclerosis (MS). Approval of Tyruko® by the European Medicines Agency is also expected imminently.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance